观察奥沙利铂联合卡培他滨治疗晚期结肠癌的临床疗效及安全性

Observation on clinical curative effect and safety of oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer

目的研究分析奥沙利铂联合卡培他滨治疗晚期结肠癌的临床疗效及安全性。方法 300例晚期结肠癌患者,随机分为化疗组A和化疗组B,各150例。化疗组A采用奥沙利铂+亚叶酸钙+5-氟尿嘧啶进行治疗;化疗组B采用奥沙利铂+卡培他滨进行治疗。比较两组患者晚期结肠癌治疗效果;入组时和治疗结束后卡氏评分;化疗过程毒副反应发生率。结果化疗组B患者晚期结肠癌治疗总有效率为86.67%,显著高于化疗组A的76.67%,差异有统计学意义(P<0.05)。两组患者入组时卡氏评分比较,差异无统计学意义(P>0.05);治疗结束后化疗组B卡氏评分为(78.18±7.71)分,显著高于化疗组A的(70.43±7.29)分,差异有统计学意义(P<0.05)。化疗组B化疗过程毒副反应发生率为50.00%,显著低于化疗组A的65.33%,差异有统计学意义(P<0.05)。结论奥沙利铂联合卡培他滨治疗晚期结肠癌的临床疗效及安全性高,可有效缓解症状,减轻毒副作用,提高患者健康水平,值得推广。

Objective To study and analyze the clinical curative effect and safety of oxaliplatin combined with capecitabine in the treatment of advanced colorectal cancer. Methods A total of 300 advanced colorectal cancer patients were randomly divided into chemotherapy group A and chemotherapy group B, with 150 cases in each group. Chemotherapy group A received oxaliplatin ＋ calcium folinate ＋ 5-fluorouracil for treatment, and chemotherapy group B received oxaliplatin ＋ capecitabine for treatment. Comparison were made on curative effect, Karnofsky score of admission and after treatment, incidence of adverse reactions during chemotherapy process in two groups. Results Chemotherapy group B had significantly higher total treatment effective rate as 86.67% than 76.67% in chemotherapy group A, and the difference had statistical significance（P〈0.05）. Both groups had no statistically significant difference in Karnofsky score of admission（P〉0.05）. After treatment, chemotherapy group B had significantly higher Karnofsky score as（78.18±7.71） points than（70.43±7.29） points in chemotherapy group A, and the difference had statistical significance（P〈0.05）. Chemotherapy group B had obviously lower incidence of adverse reactions in chemotherapy process as 50.00% than 65.33% in chemotherapy group A, and the difference had statistical significance（P〈0.05）. Conclusion Combination of oxaliplatin and capecitabine shows high clinical curative effect and safety in the treatment of advanced colorectal cancer, which can effectively relive symptoms, reduce adverse effect and improve level of patients’ health. So it is worth promoting.